BioSpace News Archive

Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB).

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”) today announced its financial results for the fourth quarter and full year ended December 31, 2023.

Amicus Therapeutics announced that management will participate in upcoming presentations at the following investor conferences in March.

Cullinan Oncology, Inc., a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, announced the U.S. Food and Drug Administration has cleared its Investigational New Drug application for CLN-619 in relapsed/refractory multiple myeloma.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2023 financial results on Tues., March 12, 2024, before the open of the U.S. financial markets.

Replicate Bioscience will be participating in the following upcoming investor meetings.

Dermavant Sciences announced that new ADORING data including treatment of patients with skin of color from Phase 3 trials of VTAMA® cream, 1% in adults and children 2 years of age and older with atopic dermatitis will be presented at the 2024 American Academy of Dermatology Annual Meeting, to be held from March 8-12 in San Diego, California.

ROME Therapeutics today announced that Rosana Kapeller, M.D., Ph.D., President, CEO and Co-founder of ROME, and other members of the ROME Senior Leadership Team will participate in the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, in Boston, Massachusetts.

Vivani Medical, Inc. announced that it has entered into a securities purchase agreement with an institutional investor to purchase 3,947,368 shares of common stock and warrants to purchase up to an aggregate of 3,947,368 shares of common stock at a purchase price of $3.80 per share and accompanying warrant in a registered direct offering.

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2023 and provided a business update.